Paper6968614
Hydrallazine in hypertension: is there a safe dose?
Bing RF and 3 others. Br Med J, 1980. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Hydrallazine in hypertension: is there a safe dose? Papers, record 6968614. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6968614
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydralazine | Major topic |
| Hypertension | Major topic |
| Adult | |
| Antibodies | |
| Antibodies, Antinuclear | |
| DNA | |
| Female | |
| Humans | |
| Lupus Erythematosus, Systemic | |
| Male | |
| Middle Aged |
Source PubMed
References3
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4912962 | Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. | J Lab Clin Med | 1970 | https://conductscience.org/library/papers/4912962 | PubMed |
| 2 | 4403571 | Simplified method for determining acetylator phenotype. | Br Med J | 1972 | https://conductscience.org/library/papers/4403571 | PubMed |
| 3 | 4581906 | Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. | Am J Med | 1973 | https://conductscience.org/library/papers/4581906 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 20544243 | Acrylamine-induced autoimmune phenomena. | Clin Rheumatol | 2010 | https://conductscience.org/library/papers/20544243 | PubMed |
| 7066169 | The addition of prazosin to standard triple therapy in the treatment of severe hypertension. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7066169 | PubMed |
| 7011656 | Acetylator phenotype and lupus erythematosus. | Clin Pharmacokinet | 1981 | https://conductscience.org/library/papers/7011656 | PubMed |
| 6984902 | Endralazine in patients with severe hypertension and renal insufficiency. | Postgrad Med J | 1982 | https://conductscience.org/library/papers/6984902 | PubMed |
| 6861845 | Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period. | Eur J Clin Pharmacol | 1983 | https://conductscience.org/library/papers/6861845 | PubMed |
| 6814636 | Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus. | Br Med J (Clin Res Ed) | 1982 | https://conductscience.org/library/papers/6814636 | PubMed |
| 6786464 | Hydralazine-induced necrotising vasculitis. | Br Med J (Clin Res Ed) | 1981 | https://conductscience.org/library/papers/6786464 | PubMed |
| 6714290 | Should the acetylator phenotype be determined when prescribing hydralazine for hypertension? | Eur J Clin Pharmacol | 1984 | https://conductscience.org/library/papers/6714290 | PubMed |
| 6432120 | The lupus syndrome induced by hydralazine: a common complication with low dose treatment. | Br Med J (Clin Res Ed) | 1984 | https://conductscience.org/library/papers/6432120 | PubMed |
| 6419809 | "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. | Br Med J (Clin Res Ed) | 1984 | https://conductscience.org/library/papers/6419809 | PubMed |
| 6148121 | The third drug in hypertension. | Br Med J (Clin Res Ed) | 1984 | https://conductscience.org/library/papers/6148121 | PubMed |
| 2874821 | Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group. | Br J Clin Pharmacol | 1986 | https://conductscience.org/library/papers/2874821 | PubMed |
| 2168822 | Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. | Clin Exp Immunol | 1990 | https://conductscience.org/library/papers/2168822 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6968614
GET https://conductscience.org/api/papers/v1/6968614/authors